Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

This study is to evaluate the combination of isatuximab, iberdomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma participants who are transplant ineligible or not intended for upfront transplant. The names of the study drugs used in this research study are: isatuximab, iberdomide, bortezomib dexamethasone

NCT Number	NCT07601100
Lead Sponsor	Dana-Farber Cancer Institute
Conditions	Newly Diagnosed Multiple Myeloma
Enrollment	88 participants
Start Date	2026-06-26
Primary Completion	2029-07-01 (estimated)
Study Completion	2034-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-01